{
  "kind": "treatment",
  "slug": "risperidone-lai-risperdal-consta",
  "type": "medication",
  "name": "Risperidone Long-Acting Injection (Risperdal Consta)",
  "summary": "Risperidone LAI (Risperdal Consta) is a long-acting injectable atypical antipsychotic used in the maintenance treatment of schizophrenia and bipolar disorder.",
  "description": "Risperidone LAI, marketed as Risperdal Consta, is an extended-release injectable formulation of the atypical antipsychotic risperidone. It is administered intramuscularly every two weeks to provide sustained symptom control in schizophrenia and as maintenance therapy in bipolar I disorder. The long-acting formulation improves adherence and stabilizes plasma concentrations compared to oral risperidone. It works by antagonizing dopamine D2 and serotonin 5-HT2A receptors, helping reduce both positive and negative symptoms of psychosis.",
  "category": "medications/psychiatry",
  "tags": [
    "antipsychotic",
    "atypical",
    "long-acting injectable",
    "schizophrenia",
    "bipolar disorder"
  ],
  "metadata": {
    "drug_classes": [
      "Atypical antipsychotic"
    ],
    "therapeutic_categories": [
      "Psychiatry"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Injection"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Risperdal Consta"
    ],
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Long-term maintenance"
    ],
    "specialty_areas": [
      "Psychiatry"
    ],
    "fda_approval_year": 2003
  },
  "clinical_metadata": {
    "primary_indications": [
      "Psychosis",
      "Bipolar"
    ],
    "off_label_uses": [
      "Schizoaffective disorder",
      "Severe behavioral disturbances in dementia (not recommended in elderly with dementia due to increased mortality risk)"
    ],
    "contraindications": [
      "Hypersensitivity to risperidone",
      "Known allergy to paliperidone (active metabolite)"
    ],
    "monitoring_required": [
      "Weight and metabolic profile",
      "Extrapyramidal symptoms",
      "Prolactin levels if symptomatic"
    ],
    "efficacy_rating": {
      "Schizophrenia": 4,
      "Bipolar disorder maintenance": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "risperidone LAI",
      "Risperdal Consta",
      "long-acting risperidone"
    ],
    "synonyms": [
      "Risperidone depot",
      "Risperidone injection"
    ],
    "common_misspellings": [
      "risperidone consta",
      "risperidal consta"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Schizophrenia in adults",
        "Maintenance treatment of bipolar I disorder"
      ]
    },
    {
      "type": "mechanism",
      "text": "Risperidone LAI antagonizes dopamine D2 and serotonin 5-HT2A receptors, reducing psychotic symptoms, mood instability, and aggression."
    },
    {
      "type": "dosing",
      "adult": {
        "schizophrenia": "25 mg intramuscularly every 2 weeks; may increase to 37.5â€“50 mg based on response and tolerability.",
        "bipolar_maintenance": "25 mg intramuscularly every 2 weeks; adjust based on clinical response."
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Vial for intramuscular injection: 12.5 mg, 25 mg, 37.5 mg, 50 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Therapeutic effect begins after 3 weeks; requires oral risperidone overlap for the first 3 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "weight gain",
        "somnolence",
        "headache",
        "constipation",
        "anxiety"
      ],
      "less_common": [
        "orthostatic hypotension",
        "hyperprolactinemia"
      ],
      "serious": [
        "neuroleptic malignant syndrome",
        "tardive dyskinesia",
        "increased risk of death in elderly with dementia-related psychosis"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "Increased mortality in elderly patients with dementia-related psychosis",
        "May cause metabolic changes (weight gain, dyslipidemia, hyperglycemia)",
        "Risk of tardive dyskinesia with long-term use"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "CNS depressants",
          "risk": "Enhanced sedative effects",
          "action": "Use caution"
        },
        {
          "with": "Antihypertensive drugs",
          "risk": "Additive hypotension",
          "action": "Monitor blood pressure"
        },
        {
          "with": "Strong CYP2D6 inhibitors",
          "risk": "Increased risperidone levels",
          "action": "Dose adjustment may be needed"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Weight, BMI",
        "Fasting glucose and lipid profile",
        "Movement disorder assessment"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if potential benefit justifies risk; limited data",
      "lactation": "Excreted in breast milk; consider discontinuing nursing or the drug",
      "geriatrics": "Increased sensitivity; higher risk of stroke and death in dementia-related psychosis"
    },
    {
      "type": "tapering",
      "text": "If discontinuation is necessary, taper gradually and switch to oral antipsychotic to avoid relapse."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Requires refrigeration until use",
        "Injection should be administered in the gluteal or deltoid muscle",
        "Patients should continue oral risperidone for the first 3 weeks after starting"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "FDA Prescribing Information - Risperdal Consta",
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021346s053lbl.pdf"
        },
        {
          "label": "NHS Guidance on Risperidone LAI",
          "url": "https://www.nhs.uk/medicines/risperidone/"
        },
        {
          "label": "PubChem - Risperidone",
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Risperidone"
        }
      ]
    }
  ],
  "seo": {
    "title": "Risperidone LAI (Risperdal Consta) - Long-Acting Injectable Antipsychotic",
    "description": "Risperidone LAI (Risperdal Consta) is a long-acting injectable atypical antipsychotic for schizophrenia and bipolar I maintenance. Learn dosing, uses, side effects, and monitoring."
  }
}
